Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003811 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00003811 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 27 participants.
The verdict
NCT00003811, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Chemotherapy drugs use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of high-dose cisplatin, etoposide, and bleomycin plus amifostine in treating children who have malignant germ cell tumors.
Interventions
- DRUG cisplatin
- DRUG etoposide
- PROCEDURE conventional surgery
- DRUG amifostine trihydrate
- BIOLOGICAL bleomycin sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2000-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003811
The ClinicalTrials.gov registry entry for NCT00003811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003811 about?
NCT00003811 is a clinical study titled "Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors". RATIONALE: Chemotherapy drugs use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of high-dose cisplatin, etoposid...
What is the current status of trial NCT00003811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2000-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00003811?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), conventional surgery (PROCEDURE), amifostine trihydrate (DRUG), bleomycin sulfate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003811?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.